Classical and Vascular Ehlers-Danlos Syndrome (EDS)

Classical and Vascular Ehlers-Danlos syndrome — scientific infographic poster

Table of Contents

  1. Why Classical and Vascular Ehlers-Danlos Syndrome Are Grouped Here
  2. Classical Ehlers-Danlos Syndrome — Genetics and How Common
  3. Classical Ehlers-Danlos Syndrome — What It Looks and Feels Like
  4. Classical Ehlers-Danlos Syndrome — The 2017 Diagnostic Criteria
  5. Classical Ehlers-Danlos Syndrome — Day-to-Day Management
  6. Vascular Ehlers-Danlos Syndrome — Genetics and How Common
  7. Vascular Ehlers-Danlos Syndrome — The Warning Signs
  8. Vascular Ehlers-Danlos Syndrome — Sentinel Events and Life Expectancy
  9. Vascular Ehlers-Danlos Syndrome — Urgent Workup and Surveillance
  10. Vascular Ehlers-Danlos Syndrome — Celiprolol and the BBEST Trial
  11. Vascular Ehlers-Danlos Syndrome — Lifestyle, Surgery, Emergency Prep
  12. Vascular Ehlers-Danlos Syndrome and Pregnancy
  13. Other Rarer Ehlers-Danlos Syndrome Subtypes in Brief
  14. Genetic Counseling and Reproductive Planning
  15. Key Research Papers
  16. Connections
  17. Featured Videos

Why Classical and Vascular Ehlers-Danlos Syndrome Are Grouped Here

Of the thirteen subtypes recognized in the 2017 international Ehlers-Danlos syndrome (EDS) classification, classical Ehlers-Danlos syndrome (cEDS) and vascular Ehlers-Danlos syndrome (vEDS) are the two that almost every clinician has heard of, and the two where a specific collagen gene mutation can be confirmed in a blood test. They also sit at opposite ends of the risk spectrum. Classical Ehlers-Danlos syndrome is the "textbook" connective-tissue disorder — stretchy skin, wide scars, wobbly joints — and while it complicates life, it rarely shortens it. Vascular Ehlers-Danlos syndrome is the form that can kill you without warning. Understanding which one is on the table — or whether a third, less alarming subtype fits better — changes everything about surveillance, pregnancy planning, emergency care, and how worried a family should be.

This article walks through both in patient-friendly language, explains how they differ from hypermobile Ehlers-Danlos syndrome (the form most Ehlers-Danlos syndrome patients have), and gives a brief map of the other rarer subtypes so you know where your diagnosis fits on the larger landscape.

Classical Ehlers-Danlos Syndrome — Genetics and How Common

Classical Ehlers-Danlos syndrome is caused in more than 90% of cases by a mutation in COL5A1 or COL5A2, the two genes that code for type V collagen. Type V is a minor collagen by volume but a major regulator: it acts like a quality-control supervisor for type I collagen fibril assembly in skin, tendon, and blood vessel walls. Lose half the working copies of COL5A1 (the usual mechanism — haploinsufficiency) and the collagen bundles in your skin end up disorganized, too large, and mechanically weak.

Inheritance is autosomal dominant. One copy of the mutation is enough to cause disease, each child of an affected parent has a 50% chance of inheriting it, and men and women are affected equally. A small minority of cases (a few percent) carry a specific mutation in COL1A1 at position c.934C>T (p.Arg312Cys) that produces a classical-EDS-like phenotype, sometimes with extra vascular risk.

Estimated prevalence is roughly 1 in 20,000 to 1 in 50,000. That puts it well ahead of vascular Ehlers-Danlos syndrome for frequency but well behind hypermobile Ehlers-Danlos syndrome, which is not rare at all and may affect 1 in 500 to 1 in 5,000 depending on how it is counted.

Classical Ehlers-Danlos Syndrome — What It Looks and Feels Like

The three findings that define classical Ehlers-Danlos syndrome in the clinic are skin hyperextensibility, atrophic scarring, and generalized joint hypermobility. Each deserves a closer look.

Skin hyperextensibility. This is tested by the pinch-and-pull maneuver: a clinician grabs a fold of skin on the volar forearm (palm side) away from joints and lifts it. Classical-EDS skin stretches dramatically — typically more than 1.5 cm — and then snaps back smartly when released. It does not hang loose like cutis laxa; it recoils. The skin also feels distinctly soft and doughy, a texture most patients and their parents recognize without prompting.

Atrophic "cigarette-paper" scars. When classical-EDS skin is cut, punctured, or scraped, it heals with a wide, thin, papery scar that often darkens over time and appears to float slightly below the surrounding skin. Knees, shins, elbows, chin, and forehead are the classic sites because these are the places children fall and adults bang into things. By adulthood many patients have dozens of these scars. They are the single most specific sign for the subtype.

Generalized joint hypermobility. Measured by the Beighton score (a 9-point examination of thumb-to-forearm, fifth-finger extension, elbow hyperextension, knee hyperextension, and palms-to-floor). Most classical-EDS patients score 5 or higher in childhood, though flexibility tends to decrease with age.

Other common findings: easy bruising disproportionate to trauma, molluscoid pseudotumors (small fleshy lumps that form at pressure points like the heels and over scars), spheroid subcutaneous masses (pea-sized mobile lumps you can roll under the skin, often on shins and forearms — these are calcified fat cysts), poor wound healing, and a tendency toward hernias, rectal prolapse in childhood, and cervical insufficiency in pregnancy.

Classical Ehlers-Danlos Syndrome — The 2017 Diagnostic Criteria

The international consortium led by Fransiska Malfait published updated criteria in 2017 (American Journal of Medical Genetics, DOI below). For classical Ehlers-Danlos syndrome they define:

Major criteria (both must be present):

Minor criteria (contribute to the clinical picture):

A clinical diagnosis requires both major criteria plus at least three minor criteria. A definitive diagnosis requires genetic confirmation — a pathogenic variant in COL5A1, COL5A2, or (rarely) the specific COL1A1 Arg312Cys substitution. Modern panels run all three for a few hundred dollars and are covered by most insurance when clinical criteria are met.

Classical Ehlers-Danlos Syndrome — Day-to-Day Management

There is no disease-modifying drug for classical Ehlers-Danlos syndrome. Management is about protecting tissue that does not heal well and screening for the small but real complications.

Wound care. Any cut in classical-EDS skin should be taken seriously. Ask your surgeon or emergency physician for:

Physical therapy and joint protection. A PT who knows connective-tissue disease can design a low-impact strengthening program that stabilizes joints without stretching already-lax ligaments. Isometric work, closed-chain exercises, bracing of the most unstable joints (wrists, ankles, patellae), and swimming are cornerstones. Contact sports and heavy weightlifting are generally discouraged in adolescence, though this is individualized.

Cardiac screening. Classical Ehlers-Danlos syndrome carries a small but measurable risk of aortic root dilation — lower than vascular Ehlers-Danlos syndrome but not zero. Most specialists recommend a baseline echocardiogram at diagnosis and repeat imaging every 3–5 years if the root is normal, more often if it is enlarged. Mitral valve prolapse is also more common than in the general population.

Dental and oral care. Gingival fragility is common; soft-bristle brushes, careful flossing, and alerting dentists before cleanings (which can cause bruising) reduce trouble.

Life expectancy. Normal. Classical Ehlers-Danlos syndrome is a quality-of-life disease, not a life-shortening one.

Vascular Ehlers-Danlos Syndrome — Genetics and How Common

Vascular Ehlers-Danlos syndrome is caused in more than 95% of confirmed cases by a mutation in COL3A1, the gene for type III collagen. Type III is the collagen that reinforces the walls of medium and large arteries, the bowel, and the uterus — precisely the tissues that rupture in this disease. A small number of cases are caused by rare variants in COL1A1 or in the gene for type I collagen processing enzymes.

Inheritance is again autosomal dominant, though roughly half of cases are de novo — the affected person is the first in their family, with no parental history. Estimated prevalence is 1 in 50,000 to 1 in 200,000, though many experts suspect it is under-diagnosed because sudden deaths from unexplained dissection or bowel rupture are often not worked up genetically.

Vascular Ehlers-Danlos Syndrome — The Warning Signs

Vascular Ehlers-Danlos syndrome does not look like classical Ehlers-Danlos syndrome. The skin is not especially hyperextensible; instead it is thin and translucent, so much so that a web of veins is clearly visible on the chest, breasts, and abdomen in adults who are not thin. The face has a distinctive appearance called acrogeria: a thin narrow face, prominent cheekbones, thin nose, thin lips, hollowed cheeks, large-looking eyes that appear to protrude, and earlobes that are small or completely absent. Hands and feet look older than the person's age.

Joint hypermobility, if present, is usually limited to the small joints of the fingers and toes, not the large-joint generalized hypermobility of classical or hypermobile Ehlers-Danlos syndrome. Many vEDS patients do not feel unusually flexible at all.

The feature that is usually dramatic is bruising. Spontaneous or very-light-trauma bruises — sometimes large, sometimes appearing in sheets — are often the first thing a parent or partner notices. Children with vEDS are sometimes investigated for child abuse or clotting disorders before the real diagnosis is made. Varicose veins in young people, premature aging of the hands, and a history of pneumothorax (collapsed lung) also show up repeatedly.

Vascular Ehlers-Danlos Syndrome — Sentinel Events and Life Expectancy

The reason vEDS is feared is that the first serious presentation is often a sentinel event — a sudden, severe, sometimes fatal rupture of an artery or hollow organ. The three classic events are:

The landmark 2014 natural-history study by Melanie Pepin and Peter Byers at the University of Washington (Genetics in Medicine, DOI below) followed 1,231 confirmed COL3A1-positive patients and found:

These are grim numbers, but they reflect a cohort diagnosed largely after a sentinel event. Earlier genetic diagnosis, aggressive surveillance, and celiprolol are shifting the curve. Patients diagnosed proactively — often because a relative had an event — are doing substantially better than the historical average.

Vascular Ehlers-Danlos Syndrome — Urgent Workup and Surveillance

If vEDS is suspected clinically, the workup moves fast. A reasonable protocol:

Vascular Ehlers-Danlos Syndrome — Celiprolol and the BBEST Trial

For decades there was no drug proven to change vEDS outcomes. That changed with the BBEST trial (Beta-Blockers in Ehlers-Danlos Syndrome Treatment), published by Ong, Ardant, and colleagues in The Lancet in 2010. The trial randomized 53 patients with clinically diagnosed vEDS (33 with confirmed COL3A1 mutations) to celiprolol — a cardioselective beta-blocker with partial beta-2 agonist activity — versus no treatment, and followed them for a mean of five years.

Celiprolol reduced arterial events (dissection or rupture) by roughly 36% relative risk — enough of a benefit that the trial was stopped early for efficacy. Celiprolol became the first and still the only vEDS-specific drug endorsed by international guidelines.

Typical dosing starts at 100 mg twice daily and titrates up to 200 mg twice daily (total 400 mg/day) as blood pressure and heart rate tolerate. The goal is not aggressive blood-pressure lowering but a steady reduction in arterial wall stress. Celiprolol is not sold in the United States and has to be imported — a frustrating logistical fact that vEDS clinics help patients navigate. Alternative beta-blockers (atenolol, metoprolol, bisoprolol) are sometimes substituted when celiprolol is unobtainable, though the evidence for those is weaker. Aggressive blood-pressure control generally, avoiding hypertensive spikes, is a goal for everyone with vEDS — see the hypertension page for general blood pressure (BP) management strategies.

Vascular Ehlers-Danlos Syndrome — Lifestyle, Surgery, Emergency Prep

Lifestyle modifications matter because tissue fragility compounds every risk.

Vascular Ehlers-Danlos Syndrome and Pregnancy

Pregnancy is the highest-risk time for a vEDS patient. Historical mortality figures cite roughly 12–15% maternal mortality per pregnancy, driven by arterial rupture, uterine rupture, and postpartum hemorrhage. Modern care at experienced centers brings this down substantially but never to baseline.

Decisions about whether to attempt pregnancy are deeply personal and deserve detailed counseling with a maternal-fetal-medicine team, a vascular surgeon, a geneticist, and the patient's partner. When pregnancy is undertaken, delivery is typically planned at a tertiary center with vascular surgery on standby, and the mode of delivery (scheduled cesarean versus vaginal) is individualized. Preimplantation genetic diagnosis is available for COL3A1 (see counseling section below). See also the Pregnancy and Ehlers-Danlos syndrome article for the broader Ehlers-Danlos syndrome-and-pregnancy picture.

Other Rarer Ehlers-Danlos Syndrome Subtypes in Brief

The 2017 classification recognizes thirteen Ehlers-Danlos syndrome subtypes. Beyond hypermobile, classical, and vascular, the others are rare but worth naming so patients know whether to seek out a specialist:

If any of these labels fit your clinical picture better than hypermobile Ehlers-Danlos syndrome, ask your geneticist to broaden the sequencing panel. Many of them have specific surveillance recommendations that are missed if the diagnosis is left at "Ehlers-Danlos syndrome, unspecified."

Genetic Counseling and Reproductive Planning

Any patient with confirmed or strongly suspected classical or vascular Ehlers-Danlos syndrome benefits from at least one session with a board-certified genetic counselor. The counselor can:

For vEDS, early diagnosis of relatives is not optional in the same way hEDS diagnosis sometimes feels optional. A 25-year-old second cousin who turns out to carry COL3A1 can be started on celiprolol and surveillance imaging before the first dissection — the kind of intervention that changes the rest of a life.

Key Research Papers

  1. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017. — doi:10.1002/ajmg.c.31552
  2. Bowen JM, Sobey GJ, Burrows NP, et al. Ehlers-Danlos syndrome, classical type. Am J Med Genet C Semin Med Genet. 2017. — doi:10.1002/ajmg.c.31549 (Byers and colleagues, classical-EDS review)
  3. Pepin MG, Schwarze U, Rice KM, et al. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med. 2014. — doi:10.1038/gim.2014.72
  4. Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial (BBEST). Lancet. 2010. — doi:10.1016/S0140-6736(10)60960-9

PubMed Topic Searches

For further reading, the following PubMed topic searches return current peer-reviewed work on classical and vascular Ehlers-Danlos syndrome:

  1. PubMed: Classical EDS and COL5A1/COL5A2 mutations
  2. PubMed: Vascular EDS and COL3A1 mutations
  3. PubMed: Celiprolol in vascular EDS
  4. PubMed: Aortic root dilation in EDS
  5. PubMed: Vascular EDS and pregnancy outcomes
  6. PubMed: Wound healing and surgical considerations in EDS
  7. PubMed: 2017 international EDS classification
  8. PubMed: Preimplantation genetic diagnosis for COL3A1

Back to Table of Contents

Connections

Back to Table of Contents